Dataset Information

Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

ABSTRACT: The objective of the present study was to evaluate the efficacy of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts. Gilts were vaccinated intramuscularly 56 and 35 days antepartum (on days 58 and 79 of gestation) and challenged intranasally 21 days antepartum (on day 93 of gestation) with PRRSV-1 or PRRSV-2. Regardless of the challenge strain's genotype, the vaccinated gilts carried their pregnancies to term and farrowed between days 114 and 115 of gestation. All the unvaccinated gilts aborted, between days 105 and 110 of gestation. The vaccinated gilts had a significantly lower level (P < 0.05) of PRRSV viremia and significantly higher levels (P < 0.05) of virus-neutralizing antibodies and interferon-?-secreting cells compared with the unvaccinated gilts. The mean number of PRRSV-positive cells per area of fetal tissue examined did not differ significantly between the litters from the vaccinated and unvaccinated gilts. The data presented here indicate that vaccination in late-term pregnancy with PRRSV subunit vaccine is efficacious against reproductive failure due to heterologous PRRSV-1 and PRRSV-2 infection.

SUBMITTER: Oh T

PROVIDER: S-EPMC6753889 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

Oh Taehwan T Kim Hanjin H Park Kee Hwan KH Jeong Jiwoon J Kang Ikjae I Yang Siyeon S Chae Chanhee C

Canadian journal of veterinary research = Revue canadienne de recherche veterinaire 20191001 4

The objective of the present study was to evaluate the efficacy of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts. Gilts were vaccinated intramuscularly 56 and 35 days antepartum (on days 58 and 79 of gestation) and challenged intranasally 21 days antepartum (on day 93 of gestation) with PRRSV-1 or PRRSV-2. Regardless of the challenge strain's genotype, the vaccinated gilts ca ...[more]

PMID: 31571723

Similar Datasets

Project description:BACKGROUND: The porcine reproductive and respiratory syndrome virus (PRRSV) is a rapidly evolving pathogen of swine. At present, there is a high demand for safe and more effective vaccines that can be adapted regularly to emerging virus variants. A recent study showed that, by the use of a controlled inactivation procedure, an experimental BEI-inactivated PRRSV vaccine can be developed that offers partial protection against homologous challenge with the prototype strain LV. At present, it is however not known if this vaccine can be adapted to currently circulating virus variants. In this study, two recent PRRSV field isolates (07 V063 and 08 V194) were used for BEI-inactivated vaccine production. The main objective of this study was to assess the efficacy of these experimental BEI-inactivated vaccines against homologous and heterologous challenge and to compare it with an experimental LV-based BEI-inactivated vaccine and commercial inactivated and attenuated vaccines. In addition, the induction of challenge virus-specific (neutralizing) antibodies by the different vaccines was assessed. RESULTS: In a first experiment (challenge with 07 V063), vaccination with the experimental homologous (07 V063) inactivated vaccine shortened the viremic phase upon challenge with approximately 2 weeks compared to the mock-vaccinated control group. Vaccination with the commercial attenuated vaccines reduced the duration of viremia with approximately one week compared to the mock-vaccinated control group. In contrast, the experimental heterologous (LV) inactivated vaccine and the commercial inactivated vaccine did not influence viremia. Interestingly, both the homologous and the heterologous experimental inactivated vaccine induced 07 V063-specific neutralizing antibodies upon vaccination, while the commercial inactivated and attenuated vaccines failed to do so.In the second experiment (challenge with 08 V194), use of the experimental homologous (08 V194) inactivated vaccine shortened viremia upon challenge with approximately 3 weeks compared to the mock-vaccinated control group. Similar results were obtained with the commercial attenuated vaccine. The experimental heterologous (07 V063 and LV) inactivated vaccines did not significantly alter viremia. In this experiment, 08 V194-specific neutralizing antibodies were induced by the experimental homologous and heterologous inactivated vaccines and a faster appearance post challenge was observed with the commercial attenuated vaccine. CONCLUSIONS: The experimental homologous inactivated vaccines significantly shortened viremia upon challenge. Despite the concerns regarding the efficacy of the commercial attenuated vaccines used on the farms where the field isolates were obtained, use of commercial attenuated vaccines clearly shortened the viremic phase upon challenge. In contrast, the experimental heterologous inactivated vaccines and the commercial inactivated vaccine had no or only a limited influence on viremia. The observation that homologous BEI-inactivated vaccines can provide a more or less standardized, predictable degree of protection against a specific virus variant suggests that such vaccines may prove useful in case virus variants emerge that escape the immunity induced by the attenuated vaccines.

Dataset Information

Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

Publications

Effectiveness of a commercial porcine reproductive and respiratory syndrome virus (PRRSV) subunit vaccine against heterologous PRRSV-1 and PRRSV-2 challenge in late-term pregnant gilts.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets